Citation: | WANG Yan, ZHANG Zixiong, DAI Mengyuan, TAO Zezhang, XIAO Bokui, CHEN Shiming. Effect of 5-Azacytidine on hTERT mRNA Expression and Telomerase Activity in Human Nasopharyngeal Carcinoma Cells[J]. Cancer Research on Prevention and Treatment, 2016, 43(1): 6-10. DOI: 10.3971/j.issn.1000-8578.2016.01.002 |
[1] |
Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology[J]. Nat Med, 2011, 17(3): 330-9.
|
[2] |
De Carvalho DD, Sharma S, You JS, et al. DNA methylation screening identifies driver epigenetic events of cancer cell survival[J]. Cancer Cell, 2012, 21(5): 655-67.
|
[3] |
Pa t r a SK, Be t tuz z i S. Epigene t i c DNA- ( cytos ine -5- carbon) modifications: 5-Aza-2’-deoxycytidine and DNAdemethylation[ J] Biochemistry (Mosc), 2009, 74(6): 613-9.
|
[4] |
Passweg JR, Pabst T, Blum S, et al. Azacytidine for acute myeloid leukemia in elderly or frail patients: a phaseⅡtrial (SAKK 30 /07)[J]. Leuk Lymphoma, 2014, 55(1): 87-91.
|
[5] |
Strati P, Kantarjian H, Ravandi F, et al. Phase Ⅰ/Ⅱ trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome[J]. Am J Hematol, 2015, 90(4): 276-81.
|
[6] |
Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer[J]. Trends Biochem Sci, 2013, 38(9): 426-34.
|
[7] |
Mocellin S, Pooley KA, Nitti D. Telomerase and the search for the end of cancer[J]. Trends Mol Med, 2013, 19(2): 125-33.
|
[8] |
Lamy E, Goetz V, Erlacher M, et al. hTERT: another brick in the wall of cancer cells[J]. Mutat Res, 2013, 752(2): 119-28.
|
[9] |
M Daniel, Peek GW, Tollefsbol TO. Regulation of the human catalytic subunit of telomerase (hTERT)[J]. Gene, 2012, 498(2): 13 5-46.
|
[10] |
Schoeftner S, Blasco MA. Chromatin regulation and non-coding RNAs at mammalian telomeres[J].Semin Cell Dev Biol, 2010, 21 (2): 186-93.
|
[11] |
Ng LJ, Cropley JE, Pickett HA, et al. Telomerase activity is associated with an increase in DNA methylation at the proximal subtelomere and a reduction in telomeric transcription[J]. NucleicAcids Res, 2009, 37(4): 1152-9.
|
[12] |
Wang Y, Duan HG, Chen SM, et al. Effect of RNA interference targeting human telomerase reverse transcriptase on telomerase and its related protein expression in nasopharyngeal carcinoma cells[J]. J Laryngol Otol, 2007, 121(5): 476-82.
|
[13] |
Worsham MJ, Chen KM, Meduri V, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma[J]. Arch Otolaryngol Head Neck Surg, 2006, 132(6): 668-77.
|
[14] |
Hutajulu SH, Indrasari SR, Indrawati LP, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population[J]. Molecular Cancer, 2011, 10(48): 1-9.
|
[15] |
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 20 06, 15(10): 1765-5.
|
[16] |
Li LL, Shu XS, Wang ZH, et al. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma[J]. Chin J Cancer, 2011, 30 (4): 231-9.
|
[17] |
Loyo M, Brait M, Kim MS, et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma[J]. J Cancer, 20 11, 128(6): 1393-403.
|
[18] |
Saito M, Nishikawa J, Okada T, et al. Role of DNA methylation in the development of Epstein-Barr virus associated gastric carcinoma[J]. J Med Viol, 2013, 85(1): 121-7.
|
[19] |
Bechter OE, Eisterer W, Dlaska M, et al. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia[J]. Exp Hematol, 2002, 30 (1): 26-33.
|
[20] |
Kitagawa Y, Kyo S, Takakura M, et al. Demethylating reagent 5- azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT[J]. Clin Cancer Res, 2000, 6(7): 2868-75.
|
[21] |
Dessain SK, Yu H, Reddel RR, et al. Methylation of the human telomerase gene CpG island[J]. Cancer Res, 2000, 60(3): 537-41.
|
[22] |
Zhang X, Li B, de Jonge N, et al. The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression[J]. Oncotarget, 2015, 6( 7): 4888-900.
|